A therapeutic classification of DLBCL was constructed based on the responses to drugs targeted at genetic alteration (57) and both BCL2 inhibitor and PI3K inhibitor were suggested for the MCD subgroup with poor survival and EZB subgroup with good survival. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.